Accelerated Breast Diffusion-weighted Imaging Using Multiband Sensitivity Encoding with the CAIPIRINHA Method: Clinical Experience at 3 T
Debosmita Biswas, Daniel S Hippe, Yi Wang, Michaela R DelPriore, Mladen Zečević, John R Scheel, Habib Rahbar, Savannah C Partridge, Debosmita Biswas, Daniel S Hippe, Yi Wang, Michaela R DelPriore, Mladen Zečević, John R Scheel, Habib Rahbar, Savannah C Partridge
Abstract
Purpose To examine the clinical value of multiband (MB) sensitivity encoding (SENSE)-accelerated diffusion-weighted imaging (DWI) for breast imaging by performing quantitative and qualitative comparisons with conventional diffusion-weighted echo-planar imaging, or conventional DWI (cDWI). Materials and Methods In this prospective study (ClinicalTrials.gov identifier NCT03607552), women with breast cancer were recruited from July 2018 to July 2019 to undergo additional MB SENSE DWI during clinical 3-T breast MRI examinations. The cDWI and MB SENSE DWI acquisitions were assessed both quantitatively and qualitatively. Regions of interest were defined for tumorous and normal tissue, and the tumor apparent diffusion coefficient (ADC), contrast-to-noise ratio (CNR), and signal index (SI) were calculated for both DWI methods. Three readers independently reviewed the two acquisitions side by side and provided relative image quality scores. Tumor ADC, CNR, and SI measures were compared between cDWI and MB SENSE DWI acquisitions by using a paired t test, and reader preferences were evaluated by using the sign test. Results The study included 38 women (median age, 48 years; range, 28-83 years). Overall agreement was good between cDWI and MB SENSE DWI tumor ADC measures (intraclass correlation coefficient, 0.87 [95% CI: 0.75, 0.94]), and no differences were evident in the ADC (median, 0.93 × 10-3 mm2/sec vs 0.87 ×10-3 mm2/sec; P = .50), CNR (2.2 vs 2.3; P = .17), or SI (9.2 vs 9.2; P = .23) measurements. The image quality of cDWI and MB SENSE DWI acquisitions were considered equal for 51% of images (58 of 114), whereas MB SENSE DWI was preferred more often than cDWI (37% [42 of 114] vs 12% [14 of 114]; P < .001). The preference for MB SENSE DWI was most often attributed to better fat suppression. Conclusion MB SENSE can be used to accelerate breast DWI acquisition times without compromising the image quality or the fidelity of quantitative ADC measurements. Keywords: MR-Diffusion-weighted Imaging, Breast, Comparative Studies, Technology Assessment Clinical trial registration no. NCT03607552 © RSNA, 2022.
Keywords: Breast; Comparative Studies; MR-Diffusion-weighted Imaging; Technology Assessment.
Conflict of interest statement
Disclosures of conflicts of interest: D.B. Support for present work from National Institutes of Health (NIH) (payments through institution), Philips Healthcare (in-kind support through institution), and Safeway Foundation (payments through institution). D.S.H. Support for present work from NIH grants (R01 CA207290, P30 CA015704) to institution; institution has grants from GE Healthcare, Philips Healthcare, Canon Medical Systems USA, and Siemens Healthineers. Y.W. No relevant relationships. M.R.D. In-kind support for present work from Philips Healthcare (use of the sequence); currently employed by Philips Healthcare (employment began after work on the present manuscript had concluded). M.Z. Research grant from GE Healthcare. J.R.S. Grants from Radiological Society of North America Global Oncology-Fred Hutchinson Cancer Research center and GE Healthcare, unrelated to the current work; leadership or fiduciary role in RAD-AID and Breast Health Global Initiative. H.R. Current work supported by NIH grant (R01CA207290), author is co-investigator; institution has grant from GE Healthcare, author is co-investigator, funding not related to this study. S.C.P. Current work supported by NIH grant (R01CA207290), author is principal investigator; institution has grant from GE Healthcare, author is co-investigator, funding not related to this study.
Figures





Source: PubMed
Kommende kliniske studier
-
Chinese PLA General HospitalHar ikke rekruttert ennå
-
AstraZenecaGOG Foundation; European Network of Gynaecological Oncological Trial Groups... og andre samarbeidspartnereHar ikke rekruttert ennåPlatinum-sensitive Relapsed Epithelial Ovarian Cancer | Platinum-sensitive Relapsed Fallopian Tube Cancer | Platinum-sensitive Relapsed Primary Peritoneal CancerForente stater, Thailand, Brasil, Taiwan, Japan, Tyskland, Australia, Kina, Canada, India, Sør -Korea
-
Glaukos CorporationRekrutteringOkulær hypertensjon (OHT) | Åpenvinkelglaukom (OAG)Forente stater
-
Gaziantep City HospitalHar ikke rekruttert ennåSvangerskapsdiabetes mellitus (GDM) | Obstetrisk anestesi
-
Hana SerajeddiniSt. Joseph's Health Care LondonHar ikke rekruttert ennå
-
TC Erciyes UniversityRekruttering
-
Axel BrandesAarhus University Hospital; Rigshospitalet, Denmark; University Hospital... og andre samarbeidspartnereHar ikke rekruttert ennåAtrieflimmer (AF) | Fedme og overvektDanmark
-
Fudan UniversityHar ikke rekruttert ennåPrognose | Mikrosirkulasjon | Revaskularisering | Perifer arteriesykdom (PAD) | CT perfusjon
-
Fudan UniversityHar ikke rekruttert ennåMetastatic Non-Clear Cell Renal Cell Carcinoma | Metastatic Renal Medullary Carcinomas
-
Post Graduate Institute of Medical Education and...Rekruttering
-
China Medical University HospitalHar ikke rekruttert ennåChronic Low Back Pain (cLBP)
-
Colorado State UniversityRekrutteringGastrointestinale symptomer | HudkvalitetForente stater